Regístrese
Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Hepatocellular carcinoma: Present and future
Journal Information
Vol. 150. Issue 10.
Pages 390-397 (May 2018)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 150. Issue 10.
Pages 390-397 (May 2018)
Review
DOI: 10.1016/j.medcle.2017.08.024
Hepatocellular carcinoma: Present and future
Carcinoma hepatocelular: presente y futuro
Visits
0
Carolina Armengola,b,c, Maria Rosa Sarriasa,b,d, Margarita Salaa,b,
Corresponding author
msala.germanstrias@gencat.cat

Corresponding author.
a Unidad de Hepatología, Servicio de Aparato Digestivo, Institut de Recerca Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
b Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Badalona, Barcelona, Spain
c Childhood Liver Oncology Group (c-LOG), Program of Predictive and Personalized Medicine of Cancer (PMPPC), Institut de Recerca Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain
d Innate Immunity Group, Germans Trias i Pujol Health Sciences Institute (IGTP), Badalona, Barcelona, Spain
This item has received
0
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (4)
Table 1. Patients to be included in a screening program.
Table 2. Staging system of the Barcelona Clinic Liver Cancer.
Table 3. Phase III clinical trials completed in first and second-line with molecular therapies. Survival and time to radiological progression.
Table 4. Phase III clinical trials underway with targeted molecular therapies, antiangiogenic and immunotherapeutic.
Show moreShow less
Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with over 740,000 new cases per year and the third leading cause of cancer-related death, with a growing incidence in recent years. This tumour usually arises in patients with an underlying chronic liver disease. The management of this tumour has improved over the past 2 decades: patients at risk are included in a surveillance program, a prognostic staging system has been created and, finally, new treatments particularly aimed at patients with advanced HCC have been developed. This fact has resulted in a greater interest in this tumour and several scientific societies have developed clinical practice guidelines for the management of patients with this disease. In this article, we review the current and future prospects of this tumour.

Keywords:
Hepatocellular carcinoma
Liver transplant
Radioembolization
Sorafenib
Regorafenib
Resumen

El carcinoma hepatocelular (CHC) es el sexto tumor más frecuente con más de 740.000 casos nuevos cada año y constituye la tercera causa de muerte por neoplasia, habiéndose descrito un aumento de su incidencia en los últimos años. Este tumor se desarrolla generalmente en pacientes con una enfermedad hepática crónica subyacente. En las 2 últimas décadas se ha producido un avance en su tratamiento: los pacientes de riesgo se incluyen en un programa de cribado, se ha desarrollado un sistema de estadificación pronóstica y finalmente han surgido nuevos tratamientos, sobre todo para aquellos pacientes con CHC avanzado. Este hecho ha motivado un mayor interés por este tumor y diversas sociedades científicas han elaborado guías de práctica clínica para el tratamiento de estos pacientes. En esta revisión presentamos una visión actual y futura de este tumor.

Palabras clave:
Carcinoma hepatocelular
Trasplante hepático
Radioembolización
Sorafenib
Regorafenib

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.